Tipsheet
What matters at India’s listed companies
Earnings · Hospital & Healthcare · Micro cap

Clinitech Laboratory revenue climbs 15% to ₹9.49 crore in FY26

The diagnostic firm reported steady growth for the fiscal year, with net profit rising 7% as tax expenses weighed on the bottom line.

1 earlier story on Clinitech Laboratory Ltd.
Mkt cap₹9.22 cr
P/E23.36×
ROE4.47%
Debt / eq.0.00
₹9.49 cr Standalone and consolidated revenue for FY26.

What's new

  • Revenue grew 15% to ₹9.49 crore for the fiscal year ended March 31, 2026.
  • Consolidated net profit rose 7%, held back by higher tax expenses.
  • The company has deployed ₹5.28 crore of its ₹5.78 crore IPO proceeds into diagnostic expansion.

Why this matters

For a nano-cap entity, these results show consistent, if modest, operational progress following its market debut. The successful allocation of nearly all IPO funds toward core diagnostic expansion provides a clear view of where the capital is going.

What we're watching

  • Whether the company can improve net profit margins in FY27.
  • Further updates on the diagnostic business expansion.
  • The impact of tax expenses on future quarterly earnings.

The full read

Clinitech Laboratory posted a 15% revenue increase to ₹9.49 crore for the fiscal year ended March 31, 2026. Growth was steady.

While operating profits showed improvement, consolidated net profit growth was limited to 7% because higher tax expenses tempered the gains. The filing confirms that the company has successfully deployed ₹5.28 crore of its ₹5.78 crore IPO proceeds, focusing those funds on expanding its diagnostic business. For a nano-cap company, these figures indicate steady, predictable operations in the period following its listing. The results offer no major surprises, reflecting a standard year of growth and capital deployment.

Questions answered

How did Clinitech Laboratory perform in FY26?
The company recorded a 15% increase in revenue to ₹9.49 crore. Net profit growth was more modest at 7%, largely due to increased tax obligations.
What is the status of the company's IPO proceeds?
Clinitech has utilized ₹5.28 crore of the ₹5.78 crore raised in its IPO. The funds were primarily allocated to expanding its diagnostic operations.
Are these results audited?
Yes, the company released both standalone and consolidated financial results for the year ended March 31, 2026, accompanied by a statutory auditor certificate.
Mentioned: Clinitech Laboratory Ltd · FY26 · IPO proceeds
Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.

  1. 28 May 2026 · 3:09 PM IST Clinitech Laboratory revenue climbs 15% to ₹9.49 crore in FY26
  2. today Clinitech Laboratory revenue grows 15% in FY26